4 days ago 3

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch

TipRanks

Sat, May 17, 2025, 9:30 AM 1 min read

JonesResearch downgraded Acrivon Therapeutics (ACRV) to Hold from Buy without a price target Investors may now be focused on ACR-2316 as a way to re-validate the company’s tumor-selection platform, the analyst tells investors in a research note. The firm prefers to wait for initial data from ACR-2316 in the second half of 2025 and more meaningful data in 2026 before recommending the shares. Jones would like to see some “real de-risking clinical data to comfortably” value Acrivon’s biomarker-based selection platform.

Confident Investing Starts Here:

Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on ACRV:

Disclaimer & Disclosure Report an Issue